Complete response to low-dose sorafenib in a patient with metastatic renal cell carcinoma: A case report

Authors

  • Jun Morita Department of Urology, Showa University, School of Medicine, Tokyo, Japan
  • Michio Naoe Department of Urology, Showa University, School of Medicine, Tokyo, Japan
  • Yu Ogawa Department of Urology, Showa University, School of Medicine, Tokyo, Japan
  • Takehiko Nakasato Department of Urology, Showa University, School of Medicine, Tokyo, Japan
  • Motoko Sugahara Department of Urology, Showa University, School of Medicine, Tokyo, Japan
  • Masashi Morita Department of Urology, Showa University, School of Medicine, Tokyo, Japan
  • Kohzo Fuji Department of Urology, Showa University, School of Medicine, Tokyo, Japan
  • Takashi Fukagai Department of Urology, Showa University, School of Medicine, Tokyo, Japan
  • Haruaki Sasaki Department of Urology, Showa University, Fujigaoka Hospital, Yokohama, Japan
  • Yoshio Ogawa Department of Urology, Showa University, School of Medicine, Tokyo, Japan

DOI:

https://doi.org/10.5489/cuaj.1210

Keywords:

metastatic renal cell carcinoma, sorafenib, complete response

Abstract

We present a case of a patient with metastatic renal cell carcinoma (mRCC) who was treated solely with low-dose sorafenib and achieved a complete response (CR). A 79-year-old man with cytokine-refractory mRCC involving the lung, abdominal wall, and lymph nodes was treated with low-dose sorafenib (400 mg/day) as a second-line therapy. Five months into sorafenib administration, CR was confirmed by follow-up computed tomography. No severe adverse events were observed and sorafenib treatment has been continued without appearance of new lesions. Although sorafenib has been  approved for mRCC treatment, complete clinical recovery is uncommon and has rarely been described. In this case, low-dose sorafenib appears to be sufficient for achieving CR while suppressing toxicity. Furthermore, long-term continuous administration induces the patient to obtain disease stabilization. However, considering toxicity and treatment costs, it is currently a debate whether treatment should be discontinued or sustained after CR.

Downloads

Download data is not yet available.

Downloads

Published

2013-05-13

How to Cite

Morita, J., Naoe, M., Ogawa, Y., Nakasato, T., Sugahara, M., Morita, M., Fuji, K., Fukagai, T., Sasaki, H., & Ogawa, Y. (2013). Complete response to low-dose sorafenib in a patient with metastatic renal cell carcinoma: A case report. Canadian Urological Association Journal, 7(5-6), e351–4. https://doi.org/10.5489/cuaj.1210

Issue

Vol. 7 No. 5-6 (2013): CUAJ May

Section

Case Report

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.